WHO – Page 24 – Pharma.Tips

API site WHO GMP risk during WHO inspection – avoiding repeat WHO observations

Mitigating API Site Risks During WHO Inspections: A Practical Playbook Pharmaceutical manufacturers face a growing imperative to maintain compliance with WHO Good Manufacturing Practice (GMP) standards. The increasing scrutiny during…

Repeated GMP deviations during internal audit – evidence package for inspection defense

Addressing Persistent GMP Deviations During Internal Audits: A Playbook for Compliance In the complex world of pharmaceutical manufacturing, repeated GMP deviations during internal audits can threaten product quality, regulatory standing,…

Uncontrolled SOP changes during scale-up – FDA/EMA inspection citation risk

Managing Uncontrolled SOP Changes During Scale-Up to Mitigate FDA/EMA Inspection Risks Uncontrolled changes to Standard Operating Procedures (SOPs) during scale-up can lead to significant compliance risks, resulting in potential citations…

Inadequate GMP training during scale-up – CAPA framework to prevent recurrence

Preventing Recurrences of Inadequate GMP Training During Scale-Up: A Comprehensive Playbook In the dynamic landscape of pharmaceutical manufacturing, inadequate GMP training during the scale-up phase can jeopardize both product quality…

Inconsistent GMP interpretation during regulatory inspection – FDA/EMA inspection citation risk

“`html Strategies for Managing Inconsistent GMP Interpretation during Regulatory Inspections In the pharmaceutical manufacturing sector, inconsistent interpretations of Good Manufacturing Practices (GMP) during regulatory inspections can lead to serious risks,…

Uncontrolled SOP changes during scale-up – how to rebuild GMP maturity

Addressing Uncontrolled SOP Changes During Scale-Up to Enhance GMP Maturity In the highly regulated pharmaceutical environment, uncontrolled changes to Standard Operating Procedures (SOPs) during the scale-up phase can jeopardize both…

Poor change control discipline during routine manufacturing – FDA/EMA inspection citation risk

“`html Understanding and Addressing Poor Change Control in Routine Manufacturing In the pharmaceutical manufacturing industry, maintaining rigorous change control processes is essential to ensuring compliance with Good Manufacturing Practices (GMP).…

Poor change control discipline during routine manufacturing – root cause analysis inspectors expect

Resolving Poor Change Control Discipline in Routine Manufacturing: An Actionable Playbook In today’s highly regulated pharmaceutical environment, maintaining strict change control procedures is vital to ensure product quality and compliance…

Weak management oversight during technology transfer – root cause analysis inspectors expect

Addressing Weak Management Oversight During Technology Transfer: A Root Cause Analysis Playbook In the landscape of pharmaceutical manufacturing, technology transfer plays a pivotal role in ensuring the successful transition of…

Weak management oversight during scale-up – root cause analysis inspectors expect

Addressing Weak Management Oversight During Scale-Up: A Comprehensive Playbook for Inspectors Weak management oversight during the scale-up phase of pharmaceutical manufacturing poses significant risks to quality, compliance, and regulatory approval.…

Inadequate GMP training during routine manufacturing – evidence package for inspection defense

Addressing Inadequate GMP Training during Routine Manufacturing for Inspection Readiness In the complex landscape of pharmaceutical manufacturing, inadequate GMP training can lead to serious compliance violations and operational inefficiencies. This…

Poor change control discipline during technology transfer – root cause analysis inspectors expect

Poor Change Control Discipline During Technology Transfer: Essential Steps for Root Cause Analysis In the pharmaceutical manufacturing sector, maintaining strict adherence to change control processes is critical for ensuring product…